Corpus Luteum Hormones

DrugDrug NameDrug Indication
DB00396Progesterone**Gelatinized capsules** The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea [FDA label]. **Vaginal gel** Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel [F3898]. **Vaginal insert** This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women [F3901]. **Injection (intramuscular)** This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer [F3907]. **Tablets, contraceptive** The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy [F3904].
DB00603Medroxyprogesterone acetateUsed as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.
DB06789Hydroxyprogesterone caproateHydroxyprogesterone caproate is indicated for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth. (1)
DB13610FlumedroxoneNot Available
DB11859BrexanoloneBrexanolone is a synthetic neuroactive steroid gamma-aminobutyric acid A (GABA(a)) receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adult women [FDA Label][A176080, A176083, F4063, F4066, F4072].
DrugDrug NameTargetType
DB00396ProgesteroneProgesterone receptortarget
DB00396ProgesteroneEstrogen receptor alphatarget
DB00396ProgesteroneSteroid 17-alpha-hydroxylase/17,20 lyasetarget
DB00396ProgesteroneCytochrome P450 2C19enzyme
DB00396ProgesteroneCytochrome P450 2C9enzyme
DB00396ProgesteroneCytochrome P450 3A4enzyme
DB00396ProgesteroneCytochrome P450 3A5enzyme
DB00396ProgesteroneCytochrome P450 3A7enzyme
DB00396ProgesteroneP-glycoprotein 1transporter
DB00396ProgesteroneSolute carrier family 22 member 2transporter
DB00396ProgesteroneSolute carrier family 22 member 1transporter
DB00396ProgesteroneSolute carrier family 22 member 3transporter
DB00396ProgesteroneBile salt export pumptransporter
DB00396ProgesteroneMultidrug resistance-associated protein 1transporter
DB00396ProgesteroneSodium/bile acid cotransportertransporter
DB00396ProgesteroneSteroid 17-alpha-hydroxylase/17,20 lyaseenzyme
DB00396ProgesteroneCytochrome P450 1A1enzyme
DB00396ProgesteroneCytochrome P450 1B1enzyme
DB00396ProgesteroneCytochrome P450 2A6enzyme
DB00396ProgesteroneCytochrome P450 2D6enzyme
DB00396ProgesteroneMineralocorticoid receptortarget
DB00396ProgesteroneKappa-type opioid receptortarget
DB00396ProgesteroneAlpha-1-acid glycoprotein 1target
DB00396ProgesteroneGlucocorticoid receptortarget
DB00396ProgesteroneAndrogen receptortarget
DB00396ProgesteroneSex hormone-binding globulintarget
DB00396ProgesteroneSolute carrier organic anion transporter family member 1B1transporter
DB00396ProgesteroneATP-binding cassette sub-family G member 2transporter
DB00396ProgesteroneEstrogen receptor betatarget
DB00396ProgesteroneSolute carrier organic anion transporter family member 1B3transporter
DB00603Medroxyprogesterone acetateProgesterone receptortarget
DB00603Medroxyprogesterone acetateEstrogen receptor alphatarget
DB00603Medroxyprogesterone acetateCytochrome P450 3A4enzyme
DB00603Medroxyprogesterone acetateCytochrome P450 2C8enzyme
DB00603Medroxyprogesterone acetate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
DB00603Medroxyprogesterone acetateCytochrome P450 2C9enzyme
DB00603Medroxyprogesterone acetateCytochrome P450 3A1enzyme
DB06789Hydroxyprogesterone caproateProgesterone receptortarget
DB06789Hydroxyprogesterone caproateCytochrome P450 3A4enzyme
DB06789Hydroxyprogesterone caproateCytochrome P450 3A5enzyme
DB06789Hydroxyprogesterone caproateCytochrome P450 2C19enzyme
DB11859BrexanoloneGABA-A receptor (anion channel)target
DB11859BrexanoloneAldose reductaseenzyme